Innoviva (NASDAQ:INVA – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of $0.34 per share and revenue of $92.59 million for the quarter.
Innoviva (NASDAQ:INVA – Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.57 EPS for the quarter. Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The company had revenue of $91.81 million for the quarter. On average, analysts expect Innoviva to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Innoviva Trading Down 0.7 %
Innoviva stock opened at $17.79 on Tuesday. The business’s fifty day moving average is $18.04 and its 200 day moving average is $18.85. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.79 and a quick ratio of 1.64. The stock has a market capitalization of $1.11 billion, a PE ratio of 25.78 and a beta of 0.55. Innoviva has a one year low of $14.32 and a one year high of $21.28.
Analyst Ratings Changes
Check Out Our Latest Analysis on Innoviva
Innoviva Company Profile
Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Read More
- Five stocks we like better than Innoviva
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- P/E Ratio Calculation: How to Assess Stocks
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Investing In Preferred Stock vs. Common Stock
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.
